BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.62 USD
-0.02 (-3.18%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $0.62 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 |
Depreciation/Amortization & Depletion | 0.32 | 0.33 | 0.30 | 0.19 | 0.16 |
Net Change from Assets/Liabilities | 2.31 | 10.67 | 4.98 | 1.02 | 2.39 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.42 | 19.42 | 19.50 | 14.61 | 3.14 |
Net Cash From Operating Activities | -155.01 | -135.34 | -82.15 | -66.35 | -27.28 |
Property & Equipment | -0.02 | -0.14 | -0.45 | -0.32 | -0.87 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.02 | -0.14 | -0.45 | -0.32 | -0.87 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 27.54 | 0.28 | 102.45 | 256.38 | 17.83 |
Issuance (Repayment) of Debt | 0.00 | 98.60 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.02 | -2.65 | 0.00 | -9.02 | 0.18 |
Net Cash from Financing Activities | 26.52 | 96.24 | 102.45 | 247.36 | 18.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -128.50 | -39.24 | 19.85 | 180.69 | -10.14 |
Cash at Beginning of Period | 193.73 | 232.97 | 213.12 | 32.43 | 42.57 |
Cash at End of Period | 65.22 | 193.73 | 232.97 | 213.12 | 32.43 |
Diluted Net EPS | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 |
Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -35.09 | -26.79 | -179.05 | -156.80 | -106.31 |
Depreciation/Amortization & Depletion | 0.16 | 0.08 | 0.32 | 0.24 | 0.16 |
Net Change from Assets/Liabilities | -1.00 | 4.35 | 2.31 | 11.43 | 3.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -4.94 | 4.66 | 21.42 | 16.98 | 12.18 |
Net Cash From Operating Activities | -40.88 | -17.71 | -155.01 | -128.14 | -90.56 |
Property & Equipment | 0.00 | 0.00 | -0.02 | -0.02 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | -0.02 | -0.02 | -0.02 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 32.22 | 26.74 | 27.54 | 25.17 | 25.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.29 | -0.12 | -1.02 | -0.77 | -0.77 |
Net Cash from Financing Activities | 31.93 | 26.63 | 26.52 | 24.40 | 24.40 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -8.95 | 8.92 | -128.50 | -103.76 | -66.18 |
Cash at Beginning of Period | 65.22 | 65.22 | 193.73 | 193.73 | 193.73 |
Cash at End of Period | 56.27 | 74.14 | 65.22 | 89.96 | 127.55 |
Diluted Net EPS | -0.21 | -0.87 | -0.76 | -1.72 | -1.83 |